# Dyne Therapeutics, Inc.

Dyne Therapeutics, Inc. is a public company listed on Nasdaq as DYN, headquartered in Waltham, MA, United States.

## Company overview

- **Legal name:** Dyne Therapeutics, Inc.
- **Classification:** Public company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** Waltham, MA, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **Ticker:** Nasdaq: DYN
- **SEC CIK:** 0001818794

## About

Dyne Therapeutics, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001818794, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2026-03-02, it reported net income of USD -446,214,000; total assets of USD 1,186,958,000 for the fiscal period ended 2025-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2025 (period ended 2025-12-31)

- **Net income:** -$446.2M (USD -446,214,000)
- **Total assets:** $1.2B (USD 1,186,958,000)
- **Cash and equivalents:** $893.4M (USD 893,369,000)
- **Operating cash flow:** -$403.2M (USD -403,207,000)
- **Later filings:** Net income: shown as originally filed; later filings report different values for the same periods.

### FY2024 (period ended 2024-12-31)

- **Net income:** -$317.4M (USD -317,418,000)
- **Total assets:** $691.2M (USD 691,234,000)
- **Cash and equivalents:** $435.4M (USD 435,449,000)
- **Operating cash flow:** -$292.4M (USD -292,369,000)
- **Later filings:** Net income: shown as originally filed; later filings report different values for the same periods.

### FY2023 (period ended 2023-12-31)

- **Net income:** -$235.9M (USD -235,937,000)
- **Total assets:** $165.1M (USD 165,082,000)
- **Cash and equivalents:** $121.6M (USD 121,626,000)
- **Operating cash flow:** -$188.2M (USD -188,158,000)
- **Later filings:** Net income: shown as originally filed; later filings report different values for the same periods.

### FY2022 (period ended 2022-12-31)

- **Net income:** -$168.1M (USD -168,099,000)
- **Total assets:** $306.3M (USD 306,325,000)
- **Cash and equivalents:** $172.1M (USD 172,147,000)
- **Operating cash flow:** -$153.6M (USD -153,645,000)
- **Later filings:** Net income: shown as originally filed; later filings report different values for the same periods.

## Recent SEC filings

- Form 8-K — filed 2026-09-29 — period 2026-09-29 — 8-K
- Form 8-K — filed 2026-07-29 — period 2026-07-29 — 8-K
- Form 10-Q — filed 2026-07-29 — period 2026-06-30 — 10-Q
- Form 8-K — filed 2026-07-22 — period 2026-07-21 — 8-K
- Form 8-K — filed 2026-07-20 — period 2026-07-20 — 8-K
- Form 8-K — filed 2026-06-22 — period 2026-06-22 — 8-K
- Form 8-K — filed 2026-06-17 — period 2026-06-16 — 8-K
- Form 8-K — filed 2026-06-08 — period 2026-06-05 — 8-K
- Form 8-K — filed 2026-06-03 — period 2026-06-03 — 8-K
- Form 8-K — filed 2026-05-11 — period 2026-05-11 — 8-K
- Form 10-Q — filed 2026-05-11 — period 2026-03-31 — 10-Q
- Form DEF 14A — filed 2026-04-23 — period 2026-04-22 — DEF 14A

---

Updated: 2026-10-23T05:02:54.863002+00:00

Canonical page: https://altss.com/profile/dyne-therapeutics-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology